Vida Ventures
Vida Ventures is a life sciences venture firm that builds and funds biomedical companies across stages with a focus on translating innovations into therapies. The firm emphasizes company building, portfolio support and a Fellowship program, and reports a bicoastal presence with approximately $1.8 billion under management. Core principles cited on the site include patient focus, integrity, entrepreneurship, boldness, humility, collaboration and flexibility.
Vida Ventures
Boston, Massachusetts, United States, North America
Services
Venture funding
Provides equity capital to biomedical and biotechnology companies developing therapeutic assets.
Fellowship program
Operates a program to engage and develop research and company-building talent relevant to the firm’s mission and portfolio.
Strategic and company-building support
Advisory, operational and network support for portfolio companies, including assistance with partnerships, capital raises and clinical development milestones.
Venture funding
Provides equity capital to biomedical and biotechnology companies developing therapeutic assets.
Fellowship program
Operates a program to engage and develop research and company-building talent relevant to the firm’s mission and portfolio.
Strategic and company-building support
Advisory, operational and network support for portfolio companies, including assistance with partnerships, capital raises and clinical development milestones.
Portfolio
Entered into a strategic collaboration with Eli Lilly to discover and develop anticancer radiopharmaceuticals. (featured on Vida site)
#Oncology / Radiopharmaceuticals
Secured $126 million financing to advance RIPTAC cancer therapies into the clinic for major solid tumors. (featured on Vida site)
#Oncology (RIPTAC therapies)
Launched with an oversubscribed $165 million Series A financing to develop biologics for solid tumors and inflammatory & immunology diseases. (featured on Vida site)
#Biologics / Oncology and Inflammatory & Immunology
Announced a $150 million Series C financing to advance a clinical-stage precision oncology pipeline. (featured on Vida site)
#Precision oncology
Previously announced a $40 million strategic investment from Sanofi. On May 21, 2025, Vigil and Sanofi announced a definitive merger agreement under which Sanofi will acquire Vigil for $8.00 per share in cash at closing, plus a contingent value right of $2.00 per share upon first commercial sale of VG-3927; companies expect closing in third quarter 2025. (featured on Vida site and investor news)
#Neuroscience / Neurodegenerative disease
Announced closing of merger with AVROBIO and a concurrent private placement of $130.7 million. On Jan 30, 2025, Tectonic reported positive interim Phase 1b hemodynamic data for TX45 in Group 2 pulmonary hypertension in HFpEF. (featured on Vida site and company investor release)
#Therapeutic proteins / GPCR-targeted biologics
Entered into a strategic collaboration with Eli Lilly to discover and develop anticancer radiopharmaceuticals. (featured on Vida site)
#Oncology / Radiopharmaceuticals
Secured $126 million financing to advance RIPTAC cancer therapies into the clinic for major solid tumors. (featured on Vida site)
#Oncology (RIPTAC therapies)
Launched with an oversubscribed $165 million Series A financing to develop biologics for solid tumors and inflammatory & immunology diseases. (featured on Vida site)
#Biologics / Oncology and Inflammatory & Immunology
Announced a $150 million Series C financing to advance a clinical-stage precision oncology pipeline. (featured on Vida site)
#Precision oncology
Previously announced a $40 million strategic investment from Sanofi. On May 21, 2025, Vigil and Sanofi announced a definitive merger agreement under which Sanofi will acquire Vigil for $8.00 per share in cash at closing, plus a contingent value right of $2.00 per share upon first commercial sale of VG-3927; companies expect closing in third quarter 2025. (featured on Vida site and investor news)
#Neuroscience / Neurodegenerative disease
Announced closing of merger with AVROBIO and a concurrent private placement of $130.7 million. On Jan 30, 2025, Tectonic reported positive interim Phase 1b hemodynamic data for TX45 in Group 2 pulmonary hypertension in HFpEF. (featured on Vida site and company investor release)
#Therapeutic proteins / GPCR-targeted biologics